NCT03851952撤回不适用
Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Stricture Recurrence Rate
研究概览
简要总结
The ROBUST IV study is designed to collect and better understand "real-world" outcomes for men undergoing urethral dilation using the Optilume Drug Coated Balloon (DCB) for treatment of urethral stricture.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male subjects ≥ 18 years old
- •Visual confirmation of stricture via cystoscopy or retrograde urethrogram
- •Single lesion bulbar urethral stricture, less than or equal to 3.0 cm
- •Significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent urinary tract infections (UTIs).
- •IPSS score of 13 or higher
- •Lumen diameter <12F by urethrogram
- •Able to complete validated questionnaire independently
- •Qmax <15 ml/sec
- •Guidewire must be able to cross the lesion
排除标准
- •Strictures greater than 3.0 cm long
- •Subjects with greater than 1 stricture.
- •Sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel
- •Previous urethroplasty within the anterior urethra
- •Stricture due to bacterial urethritis
- •Stricture due to untreated gonorrhea
- •Stricture due to Lichen Sclerosus, or balanitis xerotica obliterans (BXO)
- •Stricture dilated or incised within the last 3 months (apart from subjects on self-catheterization)
- •Presence of local adverse factors (e.g. abnormal prostate, urethral false passage or fistula) making catheterization difficult
- •Presence of signs of obstructive voiding symptoms not directly attributable to the stricture at the discretion of the physician
- •Diagnosis of untreated and unresolved severe BPH or bladder neck contracture (BNC), at the discretion of the physician
- •Prior diagnosis of overactive bladder (OAB)
- •Diagnosis of severe stress urinary incontinence (SUI), at the discretion of the physician
- •Previous radical prostatectomy that resulted in either unresolved bladder neck contracture (BNC) and/or unresolved incontinence
- •Previous pelvic radiation
- •Diagnosis of kidney, bladder, urethral or ureteral stones in the last 6 weeks or active stone passage in the past 6 weeks
- •Diagnosed with chronic renal failure, at the discretion of the physician
- •A dependence on Botox (onabotulinumtoxinA) in the urinary system
- •Presence of a penile implant, artificial urinary sphincter, or stent(s) in the urethra or prostate
- •Known neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function
- •Previous hypospadias repair
- •Diagnosis within the last 5 years of carcinoma of the bladder or prostate or suspicion of prostate cancer (e.g. abnormal DRE or high PSA) at the discretion of the physician
- •Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affect the ability to complete the study quality of life questionnaires
- •Unwilling to use protected sex for ≥30 days post treatment
- •Unwilling to abstain or use protected sex for 90 days post treatment if sexual partner is of child bearing potential.
- •Inability to provide legally effective Informed Consent Form (ICF) and/or comply with all the required follow-up requirements
- •Active infection in the urinary system
- •History of diabetes not controlled with a hemoglobin A1-C >7.0%
- •Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function, sphincter function or poor detrusor muscle function.
- •Visible hematuria with subject urine sample without known contributing factor
研究组 & 干预措施
Optilume DCB
Other
Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
干预措施: Optilume Drug Coated Balloon (Device)
结局指标
主要结局
Stricture Recurrence Rate
时间窗: 12 months
Stricture Free Rate
Rate of Serious Adverse Events
时间窗: 3 months
Major Device or Procedure Related Serious Adverse Events
次要结局
- Change in Uroflow(3 and 12 months)
- Change in the International Prostate Symptom Score Questionnaire (IPSS)(3 and 12 months)
- Change in the EQ-5D Quality of Life Questionnaire(3 and 12 months)
- Change in the International Index of Erectile Function Questionnaire (IIEF)(3 and 12 months)
- Change in the Male Sexual Health Questionnaire (MSHQ-EjD)(3 and 12 months)
研究者
相似试验
已完成
不适用
Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture DiseaseUrethral StrictureNCT03270384Urotronic Inc.16
已完成
不适用
Resuscitative Balloon Occlusion of the Aorta in Non-traumatic Out of Hospital Cardiac ArrestOut-of-Hospital Cardiac ArrestNCT03534011Norwegian University of Science and Technology20
终止
不适用
Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical ProstatectomyUrinary IncontinenceSurgeryProstate CancerNCT04305379Johns Hopkins University31
招募中
1 期
Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile DysfunctionErectile DysfunctionNCT06264635University of Manitoba60
终止
不适用
Goal-directed Fluid Resuscitation in Acute PancreatitisAcute PancreatitisNCT00853515Brigham and Women's Hospital40